Solventum Corporation (SOLV) Stock Price, Quote & News

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temp...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 651 733 1110

Website: www.solventum.com

Address:

3M Center, Building 275-6W-20 2510 Conway Avenue East St. Paul, Maplewood, United States

OfficialStocktwitsUser Mar. 10 at 11:02 PM

$SOLV RSI: 28.05, MACD: -2.3810 Vol: 3.56, MA20: 73.58, MA50: 77.28 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

Estimize Mar. 9 at 12:00 PM

Wall St is expecting 1.35 EPS for $SOLV Q1 [Reporting 05/07 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

bigbulldaddy Mar. 2 at 2:41 PM

$SOLV Restrata integration appears slower than anticipated. Company also has a huge risk in HIS business over next 3-5 years with other SAAS AI plays ramping up. Could result in a large portion of the SOLV business/revenue breaking down. Company appears to be making AI plays itself with help from google/amazon. Obsolescence risks identified as chat bots and LLMs become comoditized.

0 · Reply

ZacksResearch Feb. 27 at 7:44 PM

$SOLV beats Q4 estimates, but shares dip 2.5% post-earnings. Why? 🤔 🔍 EPS of $1.57 topped estimates by 4.7%, marking an 11.3% year over year improvement 📈 Revenue climbed 3.7% reportedly with strong MedSurg & Dental Solutions driving organic growth See the full analysis here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-body-35653&ADID=SYND_STOCKTWITS_TWEET_2_2877011_BODY_35653

0 · Reply

ZacksResearch Feb. 27 at 6:44 PM

$SOLV beats… and still gets sold. ⚠️ Q4 earnings and revenues topped estimates, powered by organic growth across MedSurg, Dental and HIS — but margins declined, and that’s what the market is zeroing in on. Growth is there, but margin pressure is the swing factor. See the full breakdown here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-teaser-35635&ADID=SYND_STOCKTWITS_TWEET_2_2877011_TEASER_35635

0 · Reply

erevnon Feb. 27 at 2:15 PM

Keybanc maintains Solventum $SOLV at Overweight and raises the price target from $97 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:16 PM

$SOLV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.36 up 111.76% YoY • Reported revenue of $2B down -3.71% YoY • Solventum anticipates full-year 2026 organic sales growth of +2.0% to +3.0%, or +3.0% to +4.0% excluding SKU exit impact. Solventum also expects adjusted EPS of $6.40 to $6.60 and free cash flow of approximately $200 million.

0 · Reply

Estimize Feb. 25 at 1:36 AM

Wall St is expecting 1.49 EPS for $SOLV Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Feb. 23 at 2:15 PM

$SOLV Q4 earnings preview: Will tariffs dampen the momentum? 🧐 Solventum's set to announce Q4 results after market close on Feb. 26. While volume growth and cost initiatives drive optimism, tariff headwinds could weigh on margins. The combination of a positive Earnings ESP and a Zacks Rank #1, 2 or 3 increases chances of an earnings beat, but this isn't the case here. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2873298/solventum-to-post-q4-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2873298-body-34559&ADID=SYND_STOCKTWITS_TWEET_2_2873298_BODY_34559

0 · Reply

ZacksResearch Feb. 23 at 1:15 PM

$SOLV heads into Q4 with momentum — but are tariff headwinds about to test the story? The company is riding solid momentum and leaning into M&A, yet investors are laser-focused on how margins and growth trends hold up against tariff pressure. ⚠️📊 See what could move the stock after earnings 👉 https://www.zacks.com/stock/news/2873298/solventum-to-post-q4-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2873298-teaser-34558&ADID=SYND_STOCKTWITS_TWEET_2_2873298_TEASER_34558

0 · Reply

Solventum to Participate in the 2026 KeyBanc Healthcare Forum

Mar 2, 2026, 8:00 PM EST - 12 days ago

Solventum: Improvements Come Slow

Feb 27, 2026, 3:07 AM EST - 16 days ago

Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:43 PM EST - 17 days ago

Solventum beats quarterly estimates on strong demand for surgical products

Feb 26, 2026, 4:05 PM EST - 17 days ago

Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

Feb 3, 2026, 4:05 PM EST - 5 weeks ago

Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

Dec 23, 2025, 4:05 PM EST - 2 months ago

Solventum Completes Acquisition of Acera Surgical

Dec 17, 2025, 4:05 PM EST - 3 months ago

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

Dec 16, 2025, 4:05 PM EST - 3 months ago

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

Dec 11, 2025, 10:17 PM EST - 3 months ago

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Dec 2, 2025, 12:23 PM EST - 3 months ago

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 25, 2025, 4:05 PM EST - 3 months ago

Solventum to Participate in the 2025 Piper Sandler Healthcare Conference

Nov 20, 2025, 9:00 AM EST - 4 months ago

Solventum Announces $1 Billion Share Repurchase Program

Nov 20, 2025, 9:00 AM EST - 4 months ago

Solventum Announces Agreement to Acquire Acera Surgical

Nov 12, 2025, 1:51 PM EST - 4 months ago

Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 11, 2025, 9:17 AM EST - 4 months ago

Solventum: A Mixed Q3 Provides Further Support For Our Neutral Stance

Nov 6, 2025, 7:26 PM EST - 4 months ago

Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

Solventum Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:05 PM EST - 4 months ago

Solventum to Participate in the 2025 Stifel Healthcare Conference

Oct 22, 2025, 12:42 PM EDT - 5 months ago

Solventum: A Solid Performance Here

Oct 21, 2025, 5:00 PM EDT - 5 months ago

Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 16, 2025, 4:05 PM EDT - 5 months ago

Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025

Sep 9, 2025, 2:03 PM EDT - 6 months ago

Solventum Corporation (SOLV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 2:30 PM EDT - 6 months ago

Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers

Sep 5, 2025, 1:27 PM EDT - 6 months ago

Solventum Corporation (SOLV) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.

TMO

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business

TMO

Aug 28, 2025, 4:05 PM EDT - 7 months ago

Solventum to Participate in Upcoming Investor Conferences

Aug 22, 2025, 8:19 AM EDT - 7 months ago

Solventum Announces $1.75 Billion Note Tender Offers

Aug 13, 2025, 10:39 PM EDT - 7 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 7 months ago

Solventum Announces Launch of Secondary Offering of Common Stock

Aug 8, 2025, 6:53 AM EDT - 7 months ago

Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:52 PM EDT - 7 months ago

Solventum raises annual profit forecast on strength in surgical equipment

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Solventum Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 9:12 AM EDT - 8 months ago

Solventum: Appealing Again

Jul 17, 2025, 4:05 PM EDT - 8 months ago

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

Jun 18, 2025, 10:00 AM EDT - 9 months ago

Solventum Named a Best Company to Work for by U.S. News & World Report

Jun 3, 2025, 4:05 PM EDT - 10 months ago

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

May 11, 2025, 5:07 PM EDT - 11 months ago

Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

May 9, 2025, 11:02 AM EDT - 11 months ago

Solventum Corporation: Cheap, With Caveats

May 8, 2025, 6:11 PM EDT - 11 months ago

Solventum beats first-quarter profit estimates on strong surgical product sales

May 8, 2025, 4:05 PM EDT - 11 months ago

Solventum to Participate in the 2025 BofA Securities Health Care Conference

May 8, 2025, 4:05 PM EDT - 11 months ago

Solventum Reports First Quarter 2025 Financial Results

Apr 17, 2025, 4:05 PM EDT - 11 months ago

Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

Mar 21, 2025, 12:44 PM EDT - 1 year ago

3M Spin Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy

Mar 20, 2025, 9:00 AM EDT - 1 year ago

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Mar 12, 2025, 8:12 AM EDT - 1 year ago

Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Feb 28, 2025, 8:36 AM EST - 1 year ago

Solventum Corporation (SOLV) Q4 2024 Earnings Call Transcript

OfficialStocktwitsUser Mar. 10 at 11:02 PM

1 · Reply

Estimize Mar. 9 at 12:00 PM

Wall St is expecting 1.35 EPS for $SOLV Q1 [Reporting 05/07 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

bigbulldaddy Mar. 2 at 2:41 PM

0 · Reply

ZacksResearch Feb. 27 at 7:44 PM

0 · Reply

ZacksResearch Feb. 27 at 6:44 PM

0 · Reply

erevnon Feb. 27 at 2:15 PM

Keybanc maintains Solventum $SOLV at Overweight and raises the price target from $97 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:16 PM

0 · Reply

Estimize Feb. 25 at 1:36 AM

Wall St is expecting 1.49 EPS for $SOLV Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Feb. 23 at 2:15 PM

0 · Reply

ZacksResearch Feb. 23 at 1:15 PM

0 · Reply

oldwisetrader Feb. 11 at 11:42 AM

$SUUN $SOLV on cnbc talking about solar

0 · Reply

SuperGreenToday Feb. 5 at 12:51 PM

$SOLV Share Price: $76.49 Contract Selected: Jul 17, 2026 $75 Calls Buy Zone: $7.65 – $9.45 Target Zone: $13.81 – $16.88 Potential Upside: 71% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

erevnon Jan. 26 at 11:38 AM

Keybanc upgrades Solventum $SOLV from Sector Weight to Overweight and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JFDI Jan. 20 at 3:09 PM

$SOLV 50d

0 · Reply

erevnon Jan. 20 at 3:02 PM

Mizuho upgrades Solventum $SOLV from Neutral to Outperform and raises the price target from $85 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OfficialStocktwitsUser Jan. 15 at 9:49 PM

$SOLV RSI: 50.84, MACD: 0.4581 Vol: 2.25, MA20: 81.45, MA50: 80.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

bigbulldaddy Jan. 14 at 12:33 AM

$MDXG $RCEL $SOLV $VCEL I don’t think SOLV. We just bought restrata… we don’t need RCEL. Our teams could easily sell it into burn centers though.

1 · Reply

JHR Jan. 8 at 5:53 PM

$RCEL Who is going to acquire $RCEL in late 2026? $SOLV $MDXG $VCEL

0 · Reply

JackDarwin Jan. 6 at 1:18 PM

$SOLV Bullish Engulfing Candletick Pattern. Wait for the confirmation from the next day's candle.

0 · Reply

BillionerOfKing Dec. 27 at 12:48 AM

$SOLV Current Stock Price: $80.45 Contracts to trade: $80 SOLV Jan 16 2026 Call Entry: $0.80 Exit: $1.44 ROI: 80% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Dec. 24 at 8:01 PM

$SOLV makes a bold move in advanced wound care — this one matters. Solventum is buying Acera Surgical for $725M upfront, entering the tissue matrices space and expanding its MedSurg and wound care portfolio — a clear strategic push into higher-value solutions. 🧠 See what this acquisition means for the business 👉 https://www.zacks.com/stock/news/2808854/solv-acquires-acera-surgical-to-expand-advanced-wound-care-portfolio?cid=sm-stocktwits-2-2808854-teaser-26335&ADID=SYND_STOCKTWITS_TWEET_2_2808854_TEASER_26335

0 · Reply

Market Cap	11.58B
Revenue (ttm)	8.33B
Net Income (ttm)	1.56B
EPS (ttm)	N/A
PE Ratio	10.94
Forward PE	10.19
Profit Margin	18.69%
Debt to Equity Ratio	1.00

Volume	2,051,000
Avg Vol	1,136,136
Day's Range	N/A - N/A
Shares Out	173.49M
Stochastic %K	17%
Beta	0.40
Analysts	Sell
Price Target	$92.58